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Case Report
C A S E R E PORT
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Abstract
Extramammary Paget disease (EMPD) is a rare perineal neoplasia associated with a high rate of local recurrence. Surgical
excision is the standard treatment; however, this has high rates of post-operative morbidity in combination with potentially
mutilating results. Previous literature has demonstrated good response with imiquimod 5% cream in patients with vulval
EMPD, yet its effectiveness in primary perianal disease is unknown.
We describe the case of a 40-year-old woman presenting with EMPD of the perianal region, providing detailed histological
and pictoral evidence of its response to topical imiquimod 5% cream over a 16-week period, which initially resulted in remission
prior tometastatic lymph node recurrence. This case demonstrates the potential for topical imiquimod cream to avoidmajor sur-
gery and its associated complications in patients presenting with EMPD of the perianal region. We discuss the current evidence
for treating this rare condition withmedical therapy, how this case adds to current literature and possible future directions.
INTRODUCTION
Extramammary Paget disease (EMPD) is similar histologically to
Paget disease of the breast and predominantly affects external
genitalia. It is a rare malignancy and primary cutaneous disease
usually involves the vulva [1]. Secondary EMPD disease is deﬁned
as a neoplasia of a non-cutaneous tissue [2], the associated
malignancy is frequently anal and/or rectal adenocarcinoma
with involvement of the anogenital skin [3]. Histologically,
primary or cutaneous EMPD is deﬁned as a non-invasive intra-
epidermal adenocarcinoma that can spread into neighbouring
epithelial glandular appendices [4].
There are several treatment modalities described in the
management of EMPD including surgery, chemotherapy and
irradiation with variable curative rates. However, relapse can
occur in >30% of patients [5]. Surgery is the ﬁrst-line treatment;
however, surgical margins are frequently positive, resulting in
high recurrence rates after surgery [6].
Imiquimod (Aldara®, 3M Health Care Limited) is an immune
stimulator that is highly effective in the treatment of vulval
intra-epithelial neoplasia [7]. Growing evidence is beginning to
suggest a role for imiquimod 5% cream in EMPD, particularly
EMPD of vulval origin [5], in achieving disease-control or
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complete response. However, limited evidence exists for the
treatment of primary EMPD of the perianal region with
imiquimod.
In this case report, we present a female patient of 40 years
old with perianal EMPD, treated with imiquimod 5% cream.
CASE REPORT
A 40-year-old woman presented to the Dermatology outpatient
clinic with a 2-year history of a painful rash in the perianal
region associated with pruritus and erythema. The patient
denied any bowel or gynaecological symptoms. Her medical
history included erythema nodosum, polycystic ovary disease
and a body mass index (BMI) >30.
On examination, an erythematous perianal lesion was present
with associated superﬁcial excoriation (Fig. 1). An initial punch
biopsy was taken (Fig. 2A), which demonstrated a unilateral
well-demarcated eroded lesion. Immunohistochemical staining
(Fig. 2B) showed malignant cells in the epidermis, staining posi-
tively for CK7 and EMA. The tissue stained negative for CK20 and
oestrogen receptors. A diagnosis of EMPD was given.
Breast and gynaecological examinations of the patient were
normal, while a colonoscopy did not identify any evidence of
extramammary bowel disease. A computed tomography (CT)
chest, abdomen and pelvis demonstrated subcutaneous
inﬂammation of the right buttock but no evidence of disease
spread beyond the perianal skin.
Due to her elevated BMI and the perianal location of her
EMPD, it was felt that the standard option of surgical resection
by performing Mohs micrographic surgery or wide local excision
would be associated with a high risk of perioperative morbidity.
The potential for local control in a disease with a well-described
pattern for local recurrence, while avoiding potentially disﬁgur-
ing surgery, was felt to be a viable alternative option.
A trial of imiquimod cream (5%) was commenced with a
regimen of one application each night for 5 days together with
2 rest days per week. The rest period was used to allow time
for any skin inﬂammation caused by imiquimod to settle.
Analgesia (Paracetamol, Diclofenac and Tramadol) was pre-
scribed to provide pain relief for potential local skin reactions.
On review at the ﬁrst 2 weeks of treatment, the patient had tol-
erated the imiquimod 5% cream, with only two applications
missed due to vomiting secondary to a viral infection.
By Week 5, the area of erythema had visibly reduced, with a
1-cm rim of granulation tissue around its edge (Fig. 1B). The
patient’s progress was reviewed at 12 and 16 weeks, with a
stepwise regression of the EMPD identiﬁed. At 16-week examin-
ation demonstrated almost complete resolution of the perianal
erythema (Fig. 1C). Further multiple, random punch biopsies of
the perianal skin were taken 1 month later, which demon-
strated variable evidence of chronic inﬂammation with epider-
mal reaction (Fig. 2C), but no residual EMPD.
A follow-up MRI of the pelvis 16 weeks after the discontinu-
ation of treatment showed residual thickening consistent with
inﬂammation at the site of previous subcutaneous nodules.
A CT chest, abdomen and pelvis did not identify any distal
EMPD deposits.
The patient remained in remission for 18 months, however
inguinal lymphadenopathy was noted at this time and a biopsy
demonstrated adenocarcinoma suggesting malignant trans-
formation of her EMPD.
DISCUSSION
We describe the primary local treatment of perianal EMPD with
imiquimod 5% cream over a 16-week period initially resulting
in remission prior to lymph node spread at 18 months. This
provides further evidence, both in disease response and opti-
mal treatment time, which imiquimod might potentially be
considered as a ﬁrst-line treatment for perineal EMPD.
Imiquimod induces the immune response by activating
macrophages and other inﬂammatory cells by increasing syn-
thesis of pro-inﬂammatory cytokines while also producing
distinctive apoptosis in epithelial cells [7]. A retrospective case-
series of 23 patients demonstrated up to 80% clinical response
with imiquimod for EMPD of the vulva [2]. The clinical response
appears to be related to duration of imiquimod therapy in
weeks [2]; however, the optimal length of treatment time
remains to be deﬁned.
Surgical resection of perianal EMPD is an invasive procedure
associated with a high perioperative morbidity. Furthermore,
the potential of disﬁguring surgery and permanent stoma for-
mation may have a profound psychological impact on the
patient. Recurrence rates could approach up to 50% despite
adequate surgical resection margins [8].
Close monitoring of patients during the treatment period is
particularly important, both to monitor response of EMPD to
treatment and the side-effect proﬁle experienced by patients
secondary to topical imiquimod. Following the completion of
Figure 1: (A) Initial presentation with an erythematous perianal lesion with
associated superﬁcial excoriation. (B) Appearance of rash following 5 weeks and
(C) 16 weeks of treatment with 5% imiquimod cream, demonstrating stepwise
improvement. (D) Appearance of perineum at 6-month follow-up following
completion of treatment.
Figure 2: (A) Initial punch biopsy of the perianal lesion demonstrated a well-
demarcated erosive lesion with associated ﬁbrin deposition and acute inﬂam-
mation. (B) Following the 16-week course of imiquimod cream, repeat biopsies
demonstrated chronic inﬂammation with epidermal reaction and prominent
vascular proliferation, but no evidence of EMPD. Both produced with haema-
toxylin & eosin staining. Scale bar 500 μm (A) and 200 μm (B).
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imiquimod treatment, biopsies are mandatory in order to
assess residual disease, as recurrence is common. Longer term
data regarding recurrence following topical therapy, and
adequacy of subsequent surgical resection is awaited [6]. In this
case recurrence was noted by palpable inguinal lymph nodes,
with no skin or colonic lesion found. This highlights the
importance of regular follow-up in perineal EMPD, with a high
clinical index of suspicion for relapse or malignant change.
Developing an evidence-base for the use of imiquimod, as
either ﬁrst-line therapy or for disease recurrence, will be limited
by the potential number of new EMPD cases. An international
register [9] to collate data on each patient case should be consid-
ered to determine the optimal length of imiquimod treatment,
together with the long-term follow-up of patients following
treatment. In addition, it may also aid the identiﬁcation of
patient cohorts most likely to respond to imiquimod therapy.
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